Amgen Inc.

Other

YuMei Xiong

Kenneth William Walker

Jackie Zeqi Sheng

Gunasekaran Kannan

Agnes Eva Hamburger

Zhulun Wang

Yi Lin Zhang

Xiaoshan Min

Murielle M Veniant-Ellison

Jie Tang

Grant Shimamoto

Bryan D Lemon

Yang Li

Wen-Chen Yeh

Marissa Mock

Murielle Marie Veniant Ellison

Julio Cesar Medina

Jonathan B Houze

Xiaohui Du

Wang Shen

Bei Shan

Liusheng Zhu

Jian Luo

Ming Yu

Zice Fu

Paul John Dransfield

Jiwen Liu

Sean P Brown

Vatee Pattaropong

Yingcai Wang

Gayathri Swaminath

An-Rong Li

Jie Zhang

Todd J Kohn

Marc Vimolratana

Xian Yun Jiao

Yongli Su

SuJen Lai

Yi Zhang

Yong-Jae Kim

Margrit Schwarz

Jeffrey D Reagan

Qiong Cao

Li Yang

Daniel Lin

Alykhan S Motani

Jiangwen Majeti

GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.

Growth differentiation factor 15 fusion proteins

GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) polypeptides

Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) constructs

Methods of treating metabolic diseases and disorders using a GDF15 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the SFRP5 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Secreted frizzle-related protein 5 (SFRP5) binding proteins

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Substituted biphenyl GPR40 modulators

Growing community of inventors

Palo Alto, CA, United States of America

YuMei Xiong